InhaltsangabeTherapeutic Lipidology Table of Contents Chapter 1 Lipoprotein Metabolism and Vascular Biology Brian G. Choi, M.D., M.B.A. Juan J. Badimon, Ph.D. Pedro R. Moreno, M.D. Valentin Fuster, M.D., Ph.D. Lipoprotein Classification Apolipoprotein Classification Lipid Metabolism HDL Metabolism Lipoprotein Metabolism Regulation Lipids in Vascular Biology and Atherothrombosis Chapter 2 Genetic Disorders of Lipoprotein Metabolism Marina Cuchel, M.D., Ph.D. Atif Qasim, M.D. Daniel J. Rader, M.D. Lipid Disorders Involving Elevated Triglycerides Inherited Syndromes of Elevated LDL-Cholesterol Inherited Syndromes of Low LDL-Cholesterol Inherited Syndromes of Low HDL-C Inherited Syndromes of Elevated HDL-C Levels Chapter 3 International Guidelines for Dyslipidemia Management Cathleen E. Maki, R.N., M.S.N., N.P. The Canadian Guidelines The European Guidelines Joint British Societies Guidelines Chapter 4 Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes and Other Insulin Resistant States Kevin C. Maki, Ph.D. Obesity and Type 2 Diabetes Mellitus Cardiometabolic Risk Syndrome Lipid Abnormalities Associated with Insulin Resistance Functions of Insulin Excessive Production of Very-low Density Lipoproteins (VLDL): The Primary Lipid Abnormality in the Insulin Resistant State Reasons for Elevated Free Fatty Acid Levels in Insulin Resistant States Formation of Small, Dense LDL Particles Mechanisms Linking Insulin Resistance to Low HDL Cholesterol Activities of Lipoprotein and Hepatic Lipases and Their Relationships to Atherogenic Dyslipidemia Lifestyle Management for Atherogenic Dyslipidemia Drug Therapies for Atherogenic Dyslipidemia Intensification of Efforts to Lower LDL-C as a Means of Achieving the NonHDLC Goal Targeting Triglyceride-rich Lipoprotein Reduction as a Means of AchievingNonHDLC Goal Management of Diabetic Dyslipidemia Chapter 5 CReactive Protein and Other Inflammatory Markers in Cardiovascular Disease Natalie Khuseyinova, M.D. Wolfgang Koenig, M.D., Ph.D. Creactive Protein Cytokines Markers of Hemostasis, that are also Acute Phase Reactants Plasminogen Activator Inhibitor-1 DDimer Von Willebrand Factor White Blood Cell Count Lipidrelated Biomarkers Oxidised (Ox) LDL Lipoproteinassociated Phospholipase A2 (LpPLA2) Adiponectin Chapter 6 Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk Margo A. Denke, M.D. A DietEnthusiast's Summary of The Evolving Role of Diet PreStatin Cholesterol Lowering (19601987) Early Statin Years: LDL Lowering (1987-1994) Landmark Statin Trials, LDL Lowering and Eruption of the Metabolic Syndrome (1994-2004) Lipid Therapy Beyond LDL and CHD Prevention Dietary Therapies Beyond Lipids 2004present Chapter 7 Pharmacological Therapy for Cardiovascular Disease: Current and Emerging Therapies Michael H. Davidson, M.D., F.A.C.C., F.A.C.P. Statins Ezetimibe Bile Acid Sequestrants Niacin Fibrates Omega3 Fatty Acids Chapter 8 Effects of Thiazolidinediones on Serum Lipoproteins Anjli Maroo, M.D., R.V.T. W. H. Wilson Tang, M.D., F.A.C.C. Mechanisms of TZD Actions on Serum Lipoproteins Clinical Evidence of Lipid Lowering Effects of TZDs MetaAnalyses of Pioglitazone and Rosiglitazone Trials Prospective Comparative Clinical Studies Concomitant TZD and Statin Therapy Outcome Studies Future Directions Chapter 9 HighDensity Lipoproteins Peter P. Toth, M.D., Ph.D. Antiatherogenic Effects of HDL Epidemiologic Studies Evaluating the Relationship between HDL and Risk for Cardiovascular Disease The Definition and Prevalence of Low HDL Effects of Lifestyle Modification on HDL Pharmacologic Therapy for Low